Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis
Sintilimab, toripalimab, and tislelizumab are the most cost-effective PD-1 inhibitors when combined with chemotherapy for the first-line treatment of advanced ESCC in China, with ICERs below the WTP threshold. While all six PD-1 inhibitors demonstrated clinical benefits, pembrolizumab and serplulimab were less favourable from a cost-effectiveness standpoint. Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness.
Authors
- Yingtao Lin (ORCID: https://orcid.org/0000-0001-9168-0491)
- Lingli Zhang (ORCID: https://orcid.org/0000-0001-7987-0217)
- Jinhong Gong (ORCID: https://orcid.org/0000-0002-3963-3177)
- Jingjing Shang (ORCID: https://orcid.org/0000-0002-5267-933X)
- Xiaodan Qian
- Dan Su (ORCID: https://orcid.org/0000-0002-8423-1994)
- Qingli Sun
- Xin Li (ORCID: https://orcid.org/0000-0003-3951-8061)
- Man Yu (ORCID: https://orcid.org/0000-0003-2777-3620)
- Kai Xu (ORCID: https://orcid.org/0009-0000-6503-2490)
Institutions
- Qingdao University (CN)
- Fujian Medical University (CN)
- China Pharmaceutical University (CN)
- Nanjing Traditional Chinese Medicine Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Center for Global Health (US)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Changzhou No.2 People's Hospital (CN)
- Department of Health Services (US)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1080/07853890.2025.2482019
- Citations
- 8
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 16.05
Funders
- National Natural Science Foundation of China